WINTON GROUP Ltd Buys New Holdings in Solventum Corporation $SOLV

WINTON GROUP Ltd bought a new position in Solventum Corporation (NYSE:SOLV) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 44,100 shares of the company’s stock, valued at approximately $3,402,000.

Other institutional investors have also recently bought and sold shares of the company. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Solventum in the second quarter valued at about $150,066,000. SG Americas Securities LLC boosted its holdings in Solventum by 38.4% during the first quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock valued at $8,467,000 after purchasing an additional 35,982 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Solventum in the 2nd quarter valued at approximately $61,460,000. Bank of America Corp DE grew its stake in shares of Solventum by 0.6% in the 1st quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock valued at $93,561,000 after purchasing an additional 9,083 shares during the period. Finally, First Trust Advisors LP raised its holdings in shares of Solventum by 57.4% in the 1st quarter. First Trust Advisors LP now owns 334,441 shares of the company’s stock worth $21,839,000 after buying an additional 121,989 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently commented on SOLV. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings raised Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. BMO Capital Markets began coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 target price on the stock. Piper Sandler increased their target price on shares of Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, BTIG Research lifted their price target on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $92.80.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $87.43 on Friday. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $94.16. The firm has a market cap of $14.88 billion, a PE ratio of 10.69, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. The business has a fifty day moving average of $85.15 and a 200-day moving average of $76.55.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company’s revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities research analysts predict that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.